instruction:
Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.
question:
Siteman Cancer Center at Barnes-Jewish Hospital plans to open a second proton therapy center in 2020, and Mercy Hospital St. Louis expects to open its own proton center two years later, The St. Louis Post-Dispatch reported . Proton therapy zap cancerous cells with precise beams of radiation while sparing surrounding tissue. Unlike traditional X-rays, the proton beams stop at the tumor instead of traveling through the body. The new $32 million proton system planned at Barnes-Jewish Hospital will provide "pencil-beam" precision to target tumors, said Dr. Jeffrey Bradley, director of Siteman's S. Lee Kling Proton Therapy Center. It will be built next to a $20 million machine, which opened in late 2013, that uses magnets to scatter proton beams across a tumor. Siteman has treated about 800 patients with the proton therapy, close to its projections of 200 patients a year. The first proton centers built in the 1990s were known for their football-field size and up to $200 million price tag. To offset the costs, the centers marketed heavily to men with prostate cancer, despite a lack of evidence that patients have better outcomes or fewer side effects compared to cheaper treatment alternatives. In 2013, Washington University was the first to open a smaller, less-expensive proton system with one treatment room. "That's very different from other centers that went all in, borrowed money, and put in four-room centers," Bradley said. "The one room at a time idea is a very viable idea." Bradley and other radiation oncologists say a major hurdle is insurance companies' reluctance to cover proton therapy. That can cost 50 percent to 75 percent more than traditional radiation, according to industry groups. "Where the insurers like to say that proton therapy is not beneficial is often because they do not perform an adequate review of the evidence," said Scott Warwick, executive director of the National Association for Proton Therapy. "We have notified the payers that they have often either misinterpreted data, reviewed older evidence or omitted key evidence in development of their coverage policies." ___ Information from: St. Louis Post-Dispatch, http://www.stltoday.com
answer:
St. Louis medical organizations plan more proton therapy.

question:
She's disappointed not to have been able to claim ultimate victory in the battle against the human immunodeficiency virus (HIV) that causes the killer disease AIDS, but also proud that in three decades, the virus has been beaten into check. While a cure for AIDS may or may not be found in her lifetime, the 68-year-old says, achieving "remission" - where infected patients control HIV in their bodies and, crucially, can come off treatment for years - is definitely within reach. "I am personally convinced that remission...is achievable. When? I don't know. But it is feasible," she told Reuters at her laboratory at Paris's Pasteur Institute, where she and her mentor Luc Montagnier discovered HIV in 1983. "We have 'proof of concept'. We have...the famous Visconti patients, treated very early on. Now it is more than 10 years since they stopped their treatment and they are still doing very well, most of them." Sinoussi is referring to a study group of 14 French patients known as the Visconti cohort, who started on antiretroviral treatment within 10 weeks of being infected and stayed on it for an average of three years. A decade after stopping the drugs, the majority have levels of HIV so low they are undetectable. These and other isolated cases of remission, or so-called "functional cure", give hope to the 37 million people worldwide who, due to scientific progress, should now be able to live with, not have their lives cut short by, HIV. In developed countries at least - and in many poorer ones too - an HIV positive diagnosis is no longer an immediate death sentence, since patients can enjoy long, productive lives in decent health by taking antiretroviral drugs to control the virus. It's a long way from the early 1980s, when Sinoussi remembers sick, dying HIV-positive patients coming to the doors of the Pasteur and pleading with scientists there for answers. "They asked us: 'What we are going to do to cure us'," she says. At that time, she says, she knew relatively little about HIV, but what she was sure of was that these patients would never live long enough to see a treatment developed, let alone a cure. "It was very, very hard." Yet this interaction with real patients, and with their doctors and later their advocates, gave Sinoussi an important insight into what was needed to make her life in science one with meaning and impact collaboration. Working across barriers - be they scientific disciplines, cultural, religious and political divides, international borders or gender distinctions, has been and remains Sinoussi's driving force. In her earliest days, feeling disengaged while working on her PhD and itching for action in a real-life laboratory, she hustled her way in to working at the male-dominated Pasteur Institute for free with a virologist researching links between cancers and retroviruses in mice. While viruses are her thing, she has throughout her career worked with, cajoled and learned from immunologists, cancer specialists, experts in diseases of aging, pharmaceutical companies, AIDS patients, campaigners, and even the pope. "When you work in HIV, it's not only working in HIV, it's working far, far beyond," she said. Freshly armed with her Nobel award and fired up about a lack of support for proven methods of preventing HIV's spread, Sinoussi wrote an open letter to then-Pope Benedict XVI in 2009 criticising him for saying that condoms can promote the spread of AIDS. In what was widely seen as a modification of his stance in response to such criticism, Benedict said in a book a year later that use of condoms could sometimes be justified in certain limited cases as a way to fight AIDS. Sinoussi says: "HIV has shown the way to go in the field of science. You can't be isolated in your laboratory. You need to work with others." And this, she adds, is the "all together" spirit with which she advises her successors to continue after she's gone. Many will be sad to see her leave, but she has faith that her chosen field will deliver for the people who need it. "Of course, I would love to have stopped and to see we had a vaccine against HIV and another treatment that could induce remission but that's life. I encourage the new generation of scientists today to continue our work. "Science never stops," she says. "Just because a scientist stops, the science should not stop."
answer:
Science won't stop until it beats AIDS, says HIV pioneer.

question:
Eagle, 33, and Jonathan Hall, 36, had just moved out of their Brooklyn apartment when they married on March 2, the third anniversary of the blind date that brought them together. They had talked about the Appalachian Trail in their first conversation and, when it came time to plan a honeymoon, they decided to make the hike. "This was going to be an epic adventure," Eagle told The Associated Press. The couple spent a year researching, training and saving before setting off on the 2,190-mile (3,525-kilometer) journey seven days after their wedding. They knew about the new coronavirus spreading across the globe but considered themselves lucky to be trading Brooklyn for a tent on the trail, especially as New York fell under restrictions to prevent to the virus's spread. "We always figured that being out on the trail and seeing a dozen people a day was a fine position to be in," Hall said. As the pandemic grows, hikers face the difficult decision to postpone their dreams or ignore warnings and forge ahead. Like virtually every other entity in the U.S., the Appalachian Trail Conservancy began issuing COVID-19 safety guidance in March. But social distancing and hand-washing suggestions soon shifted to urging all hikers to leave the trail immediately. Shelters and privies were shut down, and volunteer programs were halted. On Wednesday, the conservancy and 29 other trail-maintaining clubs asked federal officials to close the trail until the end of the month. Though more than 3,000 "thru-hikers" set out to traverse the length of the trail each year, only about 25% successfully make the hike from Georgia to Maine, which typically takes about six months. Eagle and Hall never considered any scenario but finishing. They picked up speed as they moved into the Great Smoky Mountains along the Tennessee-North Carolina border. They woke to sunrise on Clingmans Dome the trail's highest point a view that seemed to sum up exactly what they'd hoped for from their newlywed adventure. At the same time, families across the U.S. braced for lockdowns as COVID-19 spread through cities and towns claiming more lives. Days would pass before Eagle and Hall had enough cellphone service to see just how dire the crisis had become. Fellow thru-hiker Kimberly Selvage was 30 minutes from Hot Springs, North Carolina, when she called a local hostel to confirm her reservation. "He was like, 'Ma'am, I think you've been in the woods too long; the whole world is shutting down,'" she said. That wasn't exactly the type of solitude Selvage had in mind when she quit her job, rented out her house in Las Vegas and started her hike on Feb. 26. Selvage, 51, said she thrives by herself and set out to hike the trail alone, so when whispers of closures and restrictions started to spread, she wasn't too concerned and pressed on. With her two kids in college and her parents gone, the Appalachian Trail was home for the time being, and it's where she believed she was safest. Leaving it would mean a cross-country drive exposing her to far more people than she encounters while hiking, she said. But as more trails closed and communities issued shelter-in-place orders, Selvage decided to throw in the towel for the time being after hiking 470 miles (755 kilometers). "The closures and general virus fear was changing the vibe of my hike," said Selvage, who started the hike, in part, to experience the culture of trail towns. "I chose to pause to get the full experience when it was less controversial." Selvage rented an SUV and drove back home to Las Vegas. She slept in the back of the car. Now, she's renting out a room in a friend's house until the all-clear is given to hike again. "I still think I was safer on the trail," Selvage said. For Eagle and Hall, deciding to stay or go was brutal. The couple debated day after day as they hiked over rocks and waterfalls. They hadn't yet come to terms with their choice when they loaded their backpacks into the trunk of a rental car in Tennessee. "Even right now, I don't know if we're doing the right thing," Eagle said through tears. Their decision came down to the small chance that they might catch and spread the virus, something Eagle said she couldn't live with. Most people with COVID-19 experience mild to moderate symptoms, but for others it can cause more severe illness or death. For now, they'll stay with her parents in Louisiana, which has more than 12,000 confirmed cases. "Is that better? That's hard to say," she said. They'll try to stay in shape while they wait for the all-clear. Hall joked about looking into a treadmill sale he saw online. But as the timeline becomes grimmer with each passing day, he thinks they might be saying goodbye to the AT for good. His wife disagrees and sees them starting again in a few months. Until then, she's trying to keep her disappointment in perspective. "I'm just trying to focus in on the fact that we are in such a better position than most of the world," she said. ___ Follow Sarah Blake Morgan at www.twitter.com/StorytellerSBM ___ Follow AP news coverage of the coronavirus pandemic at https://apnews.com/VirusOutbreak and https://apnews.com/UnderstandingtheOutbreak.
answer:
Coronavirus pandemic disrupts Appalachian Trail dreams.